Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
WuXi Biologics
Pharma
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.
Angus Liu
May 17, 2024 8:30am
New bill sets decoupling deadline for industry's work with WuXi
May 10, 2024 11:30am
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
May 3, 2024 7:20am
WuXi Bio pulls out of 2024 BIO convention
May 1, 2024 2:48pm
Big Pharma CEOs in China, AstraZeneca, WuXi—Fierce Pharma Asia
Mar 29, 2024 10:10am
WuXi AppTec allegedly handed over client's IP to China: report
Mar 28, 2024 10:21am